Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LIMNthis companyLiminatus Pharma, Inc. Class A Common Stock	$2.75	-1.42×	-1.48×	0×	-1.56×	-235.7%	0.0%	0.0%	0.0%	104.0%	35.6%	-68.9%	-0.15×	-0.11×	-13.75×	0.05×	0.0%	2	-28.31	1	D+
DYAIDyadic International, Inc.	$0.38	-4.09×	24.88×	24.89×	-4.53×	-156.5%	-88.3%	-579.9%	-597.6%	-597.6%	-113.6%	-18.6%	4.11×	-0.06×	-15.67×	2.68×	0.0%	3	-22.52	2	C
JSPRJasper Therapeutics, Inc.	$15.23	-0.46×	8.45×	0×	-0.1×	128.1%	0.0%	0.0%	0.0%	-1826.1%	-338.1%	-220.0%	0.3×	0.37×	0×	2.62×	0.0%	0	-45.56	2	C+
MAIAMAIA Biotechnology, Inc.	$1.09	-2.19×	20.68×	0×	384.39×	24403.2%	0.0%	0.0%	0.0%	-942.7%	-627.4%	-38.4%	0×	386.59×	0×	1.66×	0.0%	2	-2.92	1	C-
NNVCNanoViricides, Inc.	$1.37	-3.37×	3.21×	0×	-3.22×	-90.9%	0.0%	0.0%	0.0%	-94.7%	-95.7%	-27927094.0%	0×	0.36×	0×	2.66×	0.0%	3	-7.23	1	C-
SABSSAB Biotherapeutics, Inc.	$3.13	17×	0.48×	0×	4.08×	-98.8%	0.0%	0.0%	0.0%	8.8%	-30.0%	-63.3%	0.04×	-0.27×	-203.41×	9.46×	0.0%	1	7.11	3	B
Peer median	—	-2.19×	8.45×	0×	-0.1×	-90.9%	0.0%	0.0%	0.0%	-597.6%	-113.6%	-63.3%	0.04×	0.36×	0×	2.66×	0.0%	2	-7.23	2	—